These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 14603122)

  • 21. Screening for prostate cancer: reflecting on the quality of evidence from the ERSPC and PLCO studies.
    Ilic D
    Recent Results Cancer Res; 2014; 202():65-71. PubMed ID: 24531779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peptide and protein imaging mass spectrometry in cancer research.
    McDonnell LA; Corthals GL; Willems SM; van Remoortere A; van Zeijl RJ; Deelder AM
    J Proteomics; 2010 Sep; 73(10):1921-44. PubMed ID: 20510389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening.
    Smith RA; Andrews K; Brooks D; DeSantis CE; Fedewa SA; Lortet-Tieulent J; Manassaram-Baptiste D; Brawley OW; Wender RC
    CA Cancer J Clin; 2016; 66(2):96-114. PubMed ID: 26797525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening.
    Smith RA; Manassaram-Baptiste D; Brooks D; Cokkinides V; Doroshenk M; Saslow D; Wender RC; Brawley OW
    CA Cancer J Clin; 2014; 64(1):30-51. PubMed ID: 24408568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stage at diagnosis and early mortality from cancer in England.
    McPhail S; Johnson S; Greenberg D; Peake M; Rous B
    Br J Cancer; 2015 Mar; 112 Suppl 1(Suppl 1):S108-15. PubMed ID: 25734389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alu Retroelement Copy Number and Lung Cancer Risk in the Prospective Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Wong JYY; Cawthon R; Hu W; Ezennia S; Gadalla SM; Breeze C; Blechter B; Freedman ND; Huang WY; Hosgood HD; Seow WJ; Bassig BA; Rahman ML; Hayes RB; Rothman N; Lan Q
    Chest; 2022 Oct; 162(4):942-945. PubMed ID: 35609672
    [No Abstract]   [Full Text] [Related]  

  • 27. Proteomics of endometrial cancer diagnosis, treatment, and prognosis.
    Mittal P; Klingler-Hoffmann M; Arentz G; Zhang C; Kaur G; Oehler MK; Hoffmann P
    Proteomics Clin Appl; 2016 Mar; 10(3):217-29. PubMed ID: 26541900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor Staging and Grading: A Primer.
    Telloni SM
    Methods Mol Biol; 2017; 1606():1-17. PubMed ID: 28501990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective.
    Findeisen P; Neumaier M
    Clin Chem Lab Med; 2009; 47(6):666-84. PubMed ID: 19445650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New method for early detection. Urine test for prostate carcinoma (interview by Dr. Christina Berndt)].
    Schiffer E
    MMW Fortschr Med; 2007 May; 149(18):18. PubMed ID: 17672406
    [No Abstract]   [Full Text] [Related]  

  • 31. Debate rages over proteomic patterns.
    Garber K
    J Natl Cancer Inst; 2004 Jun; 96(11):816-8. PubMed ID: 15173258
    [No Abstract]   [Full Text] [Related]  

  • 32. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections.
    Wapnir IL; van de Rijn M; Nowels K; Amenta PS; Walton K; Montgomery K; Greco RS; Dohán O; Carrasco N
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1880-8. PubMed ID: 12679487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical use of tumor makers in select cancers: are you confident enough to discuss them with your patients?
    Sanchez Yamamoto D; Hallquist Viale P; Roesser K; Lin A
    Oncol Nurs Forum; 2005 Sep; 32(5):1013-22; quiz 1023-4. PubMed ID: 16136199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [At last, ERSPC and PLCO].
    Borda AP
    Actas Urol Esp; 2009 Jun; 33(6):615-8. PubMed ID: 19711742
    [No Abstract]   [Full Text] [Related]  

  • 35. [Screening for cancer].
    Caicoya Gómez-Morán M
    Aten Primaria; 1995 Oct; 16(7):441-4, 446-52. PubMed ID: 7495955
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of multiple markers to enhance clinical utility.
    Mercer DW
    Immunol Ser; 1990; 53():39-54. PubMed ID: 2100569
    [No Abstract]   [Full Text] [Related]  

  • 37. Immunocytodiagnosis of solid tumors employing panels of monoclonal antibodies.
    Mottolese M; Venturo I; Salzano M; Benevolo M; Bigotti A; Natali PG
    J Clin Lab Anal; 1993; 7(4):238-42. PubMed ID: 8360799
    [No Abstract]   [Full Text] [Related]  

  • 38. Biomarkers for the early detection of cancer: an inflammatory concept.
    Roy HK; Khandekar JD
    Arch Intern Med; 2007 Sep; 167(17):1822-4. PubMed ID: 17893302
    [No Abstract]   [Full Text] [Related]  

  • 39. Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer.
    Yang Y; Pospisil P; Iyer LK; Adelstein SJ; Kassis AI
    PLoS One; 2008; 3(11):e3661. PubMed ID: 18987750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In the search of novel urine biomarkers for the early diagnosis of prostate cancer. Intracellular or secreted proteins as the target group? Where and how to search for possible biomarkers useful in the everyday clinical practice.
    Katafigioti A; Katafigiotis I; Sfoungaristos S; Alamanis C; Stravodimos K; Anastasiou I; Roumelioti E; Duvdevani M; Constantinides C
    Arch Ital Urol Androl; 2016 Oct; 88(3):195-200. PubMed ID: 27711093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.